Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Payables: 2017-2024

Historic Payables for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $3.6 million.

  • Cidara Therapeutics' Payables rose 46.65% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 6.96%. This contributed to the annual value of $3.6 million for FY2024, which is 4.35% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Payables of $3.6 million as of FY2024, which was down 4.35% from $3.8 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Payables peaked at $4.6 million during FY2020, and registered a low of $1.3 million during FY2021.
  • For the 3-year period, Cidara Therapeutics' Payables averaged around $2.9 million, with its median value being $3.6 million (2024).
  • Its Payables has fluctuated over the past 5 years, first plummeted by 71.52% in 2021, then skyrocketed by 160.68% in 2023.
  • Over the past 5 years, Cidara Therapeutics' Payables (Yearly) stood at $4.6 million in 2020, then tumbled by 71.52% to $1.3 million in 2021, then grew by 11.22% to $1.4 million in 2022, then spiked by 160.68% to $3.8 million in 2023, then declined by 4.35% to $3.6 million in 2024.